LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== Bacterial short-chain fatty acids == Certain bacteria in the gastrointestinal tract ferment fecal fiber into SC-FAs and excrete them as waste products. The excreted SC-FAs enter the gastrointestinal walls, diffuse into the portal venous system, and ultimately flow into the systemic circulation. During this passage, they can activate the FFAR3 on cells in the intestinal wall as well as throughout the body. This activation may: suppress the appetite for food and thereby reduce overeating and the development of obesity; inhibit the liver's accumulation of fatty acids and thereby the development of fatty liver diseases; decrease blood pressure and thereby the development of hypertension and hypertension-related cardiac diseases; modulate insulin secretion and thereby the development and/or symptoms of type 2 diabetes; reduce heart rate and blood plasma norepinephrine levels and thereby lower total body energy expenditures; and suppress or delay the development of allergic asthma. The specific types of bacteria in the intestines can be modified to increase the number which make SC-FAs by using foods that stimulate the growth of these bacteria (i.e., prebiotics), preparations of SC-FA-producing bacteria (i.e., probiotics), or both methods (see synbiotics).
=== High-throughput proteomic technologies === Proteomics has steadily gained momentum over the past decade with the evolution of several approaches. Few of these are new, and others build on traditional methods. Mass spectrometry-based methods, affinity proteomics, and micro arrays are the most common technologies for large-scale study of proteins.
=== Relative biological effectiveness === After World War II, the concept of tolerance dose was replaced by that of maximum permissible dose and the concept of relative biological effectiveness was introduced. The limit was set in 1956 by the National Council on Radiation Protection & Measurements (NCRP) and the International Commission on Radiological Protection (ICRP) at 5 rem (50 mSv) per year for radiation workers and 0.5 rem per year for the general population. The unit Rem as a physical measure of radiation dose (from the English roentgen equivalent in man) was replaced by the unit Sv (sievert) in 1978. This was due to the advent of nuclear energy and its associated dangers. Prior to 1991, the equivalent dose was used both as a measure of dose and as a term for the body dose that determines the course and survival of radiation sickness. ICRP Publication 60 introduced the radiation weighting factor
=== Biomonitoring === Parmotrema perlatum is sensitive to air pollution, making it a useful bioindicator. This sensitivity is utilised in the "Hawksworth and Rose" scale, which estimates mean winter sulphur dioxide (SO2) levels in England and Wales by observing lichens on acidic and nutrient-poor bark. According to this scale, P. perlatum is found only in zones 8 to 10, indicating areas with the lowest SO2 concentrations, less than 35 micrograms per cubic metre (μg/m3). A 2022 study analyzed the effects of SO2 and nitrogen dioxide (NO2) fumigation on the chlorophyll content of Parmotrema perlatum collected from the Mount Lawu volcano in Indonesia. The results indicated that increased exposure to these pollutants leads to a significant reduction in chlorophyll levels. The study demonstrated that SO2 and NO2 negatively impact the physiological processes of the lichen, particularly its photosynthetic efficiency, demonstrating the sensitivity of P. perlatum to air pollution. Parmotrema perlatum has been effectively used in biomonitoring studies to assess environmental radioactivity. Research conducted in Turkey found that this lichen species retains radioactive caesium-137 (137Cs) from atmospheric deposition, such as fallout from the Chernobyl accident. The ecological half-life of 137Cs in Parmotrema perlatum was determined to be approximately 5.5 years, indicating its capability to monitor long-term radioactive contamination in the environment.
=== Air freight === South Africa's air freight sector serves primarily international trade rather than domestic distribution. Most air freight consists of high-value, perishable, and/or time-sensitive goods that cannot economically be transported by sea or road. Air freight represents well under 1% of South Africa's freight by mass, but carries a disproportionately high share of high-value goods. The country's air cargo network is dominated by O.R. Tambo International Airport in Johannesburg, which functions as Southern Africa's principal air cargo gateway. The airport has a total cargo capacity of 650,000 tons. According to the Department of Transport's Draft Airfreight Strategy for South Africa, 2025, by weight, 95% of all air freight flows through O.R. Tambo, with a further 3% transiting via Cape Town International, and 1% via King Shaka International. The same draft identified O.R. Tambo International and Cape Town International as the country's principal air cargo gateways. Domestic air freight accounts for less than 5% of total air freight in SA. South Africa's air freight market size was estimated at approximately R55.3 billion in 2024, with a projected CAGR of 8.75% through 2030. Also in 2024, South Africa accounted for a 19.5% share of the total air freight market in the Middle East and Africa region. The majority state-owned Airports Company South Africa (ACSA) manages all of South Africa's largest airports by cargo volume. The three largest such airports are O.R.
Sources: en.wikipedia.org
=== Rebel diplomacy === The far-left guerrilla group Revolutionary Armed Forces of Colombia (FARC), was one of the most powerful and violent groups the Colombian government had to deal with during the Colombian Conflict. They gained such strength and influence that they started to look for mechanisms to help them grow even stronger; in that sense, they developed a "Rebel Diplomacy", understood as a rebel group's conduct of foreign affairs during the development civil war for the purpose of advancing its military and political objectives. This diplomacy was used as their strategy for engaging with various international actors as they sought any type of support during various stages of the conflict. Among these international actors are the governments of other countries, non-governmental organizations (NGOs), and multinational corporations. The guerrilla group made intelligent and strategic use of social networks as a means through which to offer the international public who was witnessing the conflict a vision of their own narrative of the conflict, and to present themselves as a credible and preferable alternative to the Colombian government. To that end, FARC designed a web page and obtained support from press agencies and independent digital media, mostly European. Rebel diplomacy often emerges as a kind of counter-diplomacy aimed at discrediting the State against the insurgent group it is fighting; it is a way of taking the battle to the political arena and waging it at an international scale.
Partial-thickness: The more common type involves removing a thin layer of skin from a healthy part of the body (the donor section). Full-thickness: Involves excising a defined area of skin, with a depth of excision down to the fat. The full thickness portion of skin is then placed at the recipient site. A full-thickness skin graft is more risky, in terms of the body accepting the skin, yet it leaves only a scar line on the donor section, similar to a Cesarean-section scar. In the case of full-thickness skin grafts, the donor section will often heal much more quickly than the injury and causes less pain than a partial-thickness skin graft. A partial thickness donor site must heal by re-epithelialization which can be painful and take an extensive length of time.
=== NAADP inhibitors === Back in 2009, a selective cell-permeant NAADP antagonist, trans-Ned-19 was discovered which blocks Ca2+ signals and downstream Ca2+-dependent processes such as differentiation. Prior to that, only high concentrations of blockers of L-type Ca2+ channels (e.g. diltiazem, dihydropyridines) could be used (with obvious concerns over non-NAADP effects). A minor modification of Ned-19 produced another, more soluble antagonist, Ned-K. Although not true antagonism, the NAADP 'receptor' can self-inactivate when bound to non-releasing concentrations of NAADP itself. Such inactivating pre-pulses of NAADP were the first strategy for implicating NAADP in subsequent physiological pathways.
=== Peptide tags === Short tags on proteins are more commonly called "epitope tags." The tags on this list would fall under that category. "Epitope tagging" is the process of adding a short peptide to a protein such that it can be detected using an antibody specific to that peptide (epitope).
=== Inhibition of nitrification === Oxidative dissolution of AgNPs, which gives rise to Ag+, potentially inhibits nitrification within Ammonia oxidizing bacteria. A key step in nitrification is the oxidation of ammonia to hydroxylamine (NH2OH) catalyzed by the enzyme ammonia monooxyganase (AMO). The enzymatic activity of AMO is highly vulnerable to interference due to its intracytoplasmic location and its abundance of copper. It is speculated that Ag+ ions from AgNPs interfere with AMO's copper bonds by replacing copper with Ag+ causing a decrease in enzymatic activity, and thus nitrification.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.